Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1050 participants.
Also called NCT07238452
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,050 participants
- Registry
-
NCT07238452
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07238452. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2032-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
- Acronym
- OPTIMal AF-HF
- Condition
- Atrial Fibrillation (AF)
- Intervention (Device)
- Pulmonary Vein Isolation
- Intervention (Drug)
- Pharmacological Rate Control
- Lead sponsor
- University of British Columbia
Record details
- Record id
cardio:ct-nct07238452- Content hash
b6ebb29e4b0f49bc0506ba679858cf9eeca2cf39ed43be9ee5aa902c06e21660